Tirandamycin acts as a potent inhibitor of ribonucleic acid (RNA) polymerase in bacterial and mammalian cell-free test systems. The antibiotic inhibits the actively synthesizing template-enzyme-nascent RNA complex. Prolonged preincubation of RNA polymerase with tirandamycin prior to assay does not result in a drastic increase of tirandamycin inhibition. Tirandamycin inhibition is not reversed by further addition of deoxyribonucleic acid but is reversed upon further addition of RNA polymerase. Substantial inhibition of RNA polymerase is also obtained when the antibiotic is added at various times after initiation of the reaction. This suggests that tirandamycin interferes with the actively synthesizing template-RNA polymerase complex and inhibits chain elongation rather than chain initiation during RNA synthesis. Tirandamycin also interferes with oxidative phosphorylation in rat liver mitochondria and thus possesses two modes of action.
Tirandamycin acts as a potent inhibitor of ribonucleic acid (RNA) polymerase in bacterial and mammalian cell-free test systems. The antibiotic inhibits the actively synthesizing template-enzyme-nascent RNA complex. Prolonged preincubation of RNA polymerase with tirandamycin prior to assay does not result in a drastic increase of tirandamycin inhibition. Tirandamycin inhibition is not reversed by further addition of deoxyribonucleic acid but is reversed upon further addition of RNA polymerase. Substantial inhibition of RNA polymerase is also obtained when the antibiotic is added at various times after initiation of the reaction. This suggests that tirandamycin interferes with the actively synthesizing template-RNA polymerase complex and inhibits chain elongation rather than chain initiation during RNA synthesis. Tirandamycin also interferes with oxidative phosphorylation in rat liver mitochondria and thus possesses two modes of action.
Tirandamycin, a new antibacterial agent, was isolated from the culture broth of Streptomyces tirandis sp. n. The compound was crystallized in the form of its sodium salt and has the empirical formula C22H26NO7 .Na. The buff-colored crystals have very limited solubility in aqueous solution (co400 gg/ml). Preparation, isolation, characterization, and biological properties are described elsewhere (0. K. Sebek and C. E. Meyer, in preparation). The agent is a moderately active growth inhibitor for gram-positive bacteria in vitro but has been ineffective in the systemic treatment of experimental bacterial infections in mice. The tolerated dose (subcutaneous) is >320 mg/kg in mice.
Investigations pertaining to the mode of action of tirandamycin showed that the agent interferes with ribonucleic acid (RNA) polymerase in bacterial and mammalian cell-free systems as discussed in this paper. In addition, tirandamycin also interferes with oxidative phosphorylation in rat liver mitochondria (3).
The antibiotic thus possesses two modes of action. Tirandamycin concentrations of 100 to 200 ,g/ml inhibit both processes (RNA polymerization, oxidative phosphorylation) about equally.
MATERIALS AND METHODS
Deoxyribonucleic acid (DNA) and RNA polymerase from Escherichia coli were prepared and assayed in DNA-primed reactions as described previously (2) . One RNA polymerase unit corresponds to 1 nmole of dAT-directed adenosine triphosphate (ATP) incorporated per min.
Polyribonucleotide-mediated RNA synthesis was carried out by the method of Fox et al. (1) , except that E. coli RNA polymerase was used.
The cell-free E. coli amino acid incorporation system was prepared as described by Reusser (2) .
RNA polymerase from L-1210 cells was prepared by the method of Reusser and Bhuyan (4). Rifamycin SV was purchased from Calbiochem.
RESULTS
Effect of tirandamycin on DNA-primed RNA polymerization. The DNA-directed RNA polymerase system was inhibited substantially by tirandamycin, and a strict dose-response relationship was apparent (Fig. 1 ). An antibiotic concentration slightly higher than 100 ,ug/ml was necessary to cause 50% inhibition of the reaction. The RNA polymerase reactions primed with synthetic polydeoxyribonucleotides of known base composition were also subject to tirandamycin inhibition. An antibiotic concentration of 100 ,ug/ml caused approximately 50% inhibition of the dAT-primed ATP incorporation system ( and approximately 16%c, of cytidine triphosphate (CTP) incorporation, respectively (Table 1) .
Increasing amounts of RNA polymerase in the presence of a constant amount of tirandamycin (100 ,ug/ml) caused a gradual reversal of tirandamycin inhibition ( (Fig. 3) .
When the same inhibitor was added after 5 were then chilled in ice, and 3 ml of cold 3.5% perchloric acid, containing 50 mg of Celite per 100 ml, was added. The acid-insoluble product was collected on membrane filters (Millipore Corp.) and assayed for radioactivity. Reactions were run for 30 min at 37 C, tubes were then chilled in ice, and one drop of carrier RNA (5 mg/mI) was added. The samples were precipitated with 0.2 ml of cold 2.5 N perchloric acid containing 2 g of Celite per 100 ml. Samples were then processed as described in legend to Fig. 1. reduced to approximately 57%. In both cases, a substantial portion of RNA synthesis not inhibitable by rifamycin SV was inhibited by tirandamycin.
Effect of tirandamycin on RNA-primed RNA polymerization. RNA synthesis primed by synthetic polyribonucleotides was inhibited by tirandamycin ( Table 3 ). The extent of inhibition varied grossly depending on the particular assay system used. Poly A-mediated uridine triphosphate (UTP) incorporation was the most susceptible reaction and an inhibition of 79% was obtained. Poly U-mediated AT? incorporation was less inhibited (64% inhibition); poly Cmediated GTP incorporation was only inhibited 18%.
Effect of tirandamycin on mammalian RNA polymerase. The effect of tirandamycin on mammalian RNA polymerase was studied with a cellfree system derived from L-1210 cells. Tirandamycin effectively inhibited this system (Fig. 4 ). An antibiotic concentration of approximately 40 ,ug/ml caused 50 % inhibition of the reaction.
DISCUSSION
Tirandamycin inhibits DNA-and RNAmediated RNA synthesis in cell-free E. coli test systems. No impairment of polypeptide or DNA synthesis was observed in cell-free systems prepared as described by Reusser (2) (3) . No evidence of any interaction between DNA and tirandamycin was found by difference spectroscopy carried out as described by Reusser (2) .
Preincubation of RNA polymerase with tirandamycin prior to assay did not increase the extent of tirandamycin inhibition significantly. On the other hand, substantial inhibition of RNA synthesis was obtained while the reaction was in progress. The slopes of the resulting inhibition curves shown in Fig. 2 , reflecting the rates of tirandamycin-induced inhibition, show a small but generally progressive decline the later the antibiotic was added to the actively synthesizing reaction mixtures. In the experiments in which new chain initiation was blocked by rifamycin SV, a substantial portion of RNA synthesis insensitive to rifamycin SV inhibition and obviously reflecting chain elongation remained subject to tirandamycin inhibition. Therefore, these results indicate that tirandamycin inhibits the actively synthesizing template-RNA polymerase complex and affects chain elongation rather than chain initiation during the RNA polymerization process.
Cell-free RNA synthesis in a mammalian system was also susceptible to tirandamycin inhibition. Thus, RNA polymerase of bacterial and mammalian origin appears to be subject to inhibition by tirandamycin. 
